SRC
MRNA icon

Shufro Rose & Co’s Moderna MRNA Stock Holding History

Shufro Rose & Co’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-146,896
Closed -$17.4M – 319
2024
Q3 		$17.4M Hold
146,896
– – 1.42% 21
2024
Q2 		$17.4M Buy
146,896
+312
+0.2% +$39.5K 1.42% 21
2024
Q1 		$15.6M Buy
+146,584
New +$14.8M 1.29% 21

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Shufro Rose & Co's MRNA Position: Q4 2024 in Review

Shufro Rose & Co sold out of Moderna (MRNA) in Q4 2024, closing a stake of 146,896 shares — an estimated $17.4M sold.

Shufro Rose & Co first reported a position in MRNA in Q1 2024 and held it in 3 quarters. The position peaked at $17.4M in Q3 2024. 745 funds tracked by Wall St. Rank hold MRNA as of Q4 2024.

  • Shufro Rose & Co reported no remaining Moderna position as of Q4 2024 after selling out during the quarter.
  • Shufro Rose & Co sold 146,896 Moderna shares in Q4 2024, an estimated $17.4M.
  • Shufro Rose & Co first reported a position in Moderna in Q1 2024 and held it in 3 quarters.
  • Shufro Rose & Co's Moderna position peaked at $17.4M in Q3 2024.
  • 745 funds tracked by Wall St. Rank held Moderna as of Q4 2024.

Based on Shufro Rose & Co's 13F filing for Q4 2024, filed 25 Feb 2025.